Kitao Hiroyuki, Iimori Makoto, Kataoka Yuki, Wakasa Takeshi, Tokunaga Eriko, Saeki Hiroshi, Oki Eiji, Maehara Yoshihiko
Department of Molecular Cancer Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Taiho Pharmaceutical Co. Ltd., Tokushima, Ibaraki, Japan.
Cancer Sci. 2018 Feb;109(2):264-271. doi: 10.1111/cas.13455. Epub 2017 Dec 22.
DNA replication is one of the fundamental biological processes in which dysregulation can cause genome instability. This instability is one of the hallmarks of cancer and confers genetic diversity during tumorigenesis. Numerous experimental and clinical studies have indicated that most tumors have experienced and overcome the stresses caused by the perturbation of DNA replication, which is also referred to as DNA replication stress (DRS). When we consider therapeutic approaches for tumors, it is important to exploit the differences in DRS between tumor and normal cells. In this review, we introduce the current understanding of DRS in tumors and discuss the underlying mechanism of cancer therapy from the aspect of DRS.
DNA复制是一种基本的生物学过程，其中失调可导致基因组不稳定。这种不稳定性是癌症的标志之一，并在肿瘤发生过程中赋予遗传多样性。大量实验和临床研究表明，大多数肿瘤都经历并克服了由DNA复制扰动引起的应激，这也被称为DNA复制应激（DRS）。当我们考虑肿瘤的治疗方法时，利用肿瘤细胞与正常细胞之间DRS的差异非常重要。在这篇综述中，我们介绍了目前对肿瘤中DRS的理解，并从DRS的角度讨论癌症治疗的潜在机制。
